Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Roland Shepard

Gastroenterology Tampa, FL Medical Doctor

NPI 1326034885 CMS profile 59637

4224 N Tampania Ave, Tampa, FL 33607

Open in the dashboard

General payments

$19,868

968 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Roland Shepard of Tampa, FL is reported in the CMS Open Payments database as having received $19,868 across 968 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,371 121
2024 General $3,420 149
2023 General $3,070 150
2022 General $3,332 169
2021 General $3,218 176
2020 General $1,626 95
2019 General $1,830 108

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Roland Shepard
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Roland Shepard were reported at $3,371. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Roland Shepard Gastroenterology median Middle half National median
2019 $1,830 $417 $126–$1,100 $163
2020 $1,626 $224 $74–$624 $114
2021 $3,218 $352 $106–$1,054 $132
2022 $3,332 $448 $129–$1,270 $149
2023 $3,070 $533 $150–$1,390 $160
2024 $3,420 $605 $160–$1,606 $164
2025 $3,371 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $5,113 261 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $2,522 138 payments
  3. Janssen Biotech, Inc. $2,166 85 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $1,835 96 payments
  5. Celgene Corporation $994 61 payments
  6. Pfizer Inc. $759 40 payments
  7. RedHill Biopharma Inc. $651 35 payments
  8. VIVUS, Inc. $546 29 payments
  9. Phathom Pharmaceuticals, Inc. $521 10 payments
  10. Lilly USA, LLC $514 16 payments
  11. Other $4,246 197 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $19,651 958 payments
  2. Education $199 9 payments
  3. Consulting Fee $17 1 payment
Products named General payments · program years 2019–2025
  1. XIFAXAN $2,323 122 payments
  2. STELARA $1,618 77 payments
  3. CREON $1,615 94 payments
  4. RINVOQ $1,567 81 payments
  5. LINZESS $1,412 78 payments
  6. ENTYVIO $1,256 64 payments
  7. SKYRIZI $1,188 49 payments
  8. TREMFYA $1,001 22 payments
  9. ZEPOSIA $987 60 payments
  10. HUMIRA $886 50 payments
  11. Other $12,053 570 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

1,744

Median for Gastroenterology: 569

Drug cost

$703,398

Median for Gastroenterology: $104,976

Branded share of claims

22.2%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Stelara Ustekinumab Brand 13 $418,252
Rinvoq Upadacitinib Brand 15 $122,342
Creon Lipase/Protease/Amylase Brand 22 $47,556
Linzess Linaclotide Brand 72 $41,609
Trulance Plecanatide Brand 26 $18,995
Dexlansoprazole Dr Dexlansoprazole Brand 47 $12,349
Mesalamine Generic 23 $10,763
Alosetron Hcl Generic 18 $5,636
Sucralfate Generic 162 $4,373
Omeprazole Generic 371 $4,159

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$97,269

Medicare's payments for the services billed

Medicare patients

474

Average age 74

Services billed

1,072

309 women, 165 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 53%
Ischemic heart disease 39%
Osteoporosis 26%
Diabetes 24%
Depression 24%
Chronic kidney disease 21%
Cancer 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
$358 — —
ENTYVIO
$313 — —
RINVOQ
$268 15 —
STELARA
$201 13 —
VOQUEZNA
$201 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

968 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record